Urinary Volatile Compounds as Biomarkers for Lung Cancer

Hanai, Yosuke; Shimono, Ken; Matsumura, K; Vachani, Anil; Albelda, Steven Μ.; Yamazaki, Kunio; Beauchamp, Gary K.; Oka, Hiroaki

doi:10.1271/bbb.110760

Cited by 92 publications

(74 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the sampling method is critical, as it may alter the urine profile [3,13,14]. Despite these difficulties, there is a lot of recent research about the identification of biomarkers in urine for early and non-invasive diagnosis purposes (e.g., [15,16,17]).…”

Section: Introductionmentioning

confidence: 99%

Application and Uses of Electronic Noses for Clinical Diagnosis on Urine Samples: A Review

Capelli

Taverna

Bellini

et al. 2016

Sensors

View full text Add to dashboard Cite

The electronic nose is able to provide useful information through the analysis of the volatile organic compounds in body fluids, such as exhaled breath, urine and blood. This paper focuses on the review of electronic nose studies and applications in the specific field of medical diagnostics based on the analysis of the gaseous headspace of human urine, in order to provide a broad overview of the state of the art and thus enhance future developments in this field. The research in this field is rather recent and still in progress, and there are several aspects that need to be investigated more into depth, not only to develop and improve specific electronic noses for different diseases, but also with the aim to discover and analyse the connections between specific diseases and the body fluids odour. Further research is needed to improve the results obtained up to now; the development of new sensors and data processing methods should lead to greater diagnostic accuracy thus making the electronic nose an effective tool for early detection of different kinds of diseases, ranging from infections to tumours or exposure to toxic agents.

show abstract

Section: Introductionmentioning

confidence: 99%

Application and Uses of Electronic Noses for Clinical Diagnosis on Urine Samples: A Review

Capelli

Taverna

Bellini

et al. 2016

Sensors

View full text Add to dashboard Cite

show abstract

“…Review MS-based metabolomic platforms are increasingly applied to the screening of tumor markers and have been used in recent years for colorectal cancer [39][40][41][42][43][44][45][46], lung cancer [47][48][49][50][51][52][53], papillary thyroid carcinoma [54], oral cancer [55,56] and pancreatic cancer [57]. Here, due to space limitations, the authors review the development of metabolomics in the discovery of tumor markers only for specific malignancies with high incidence, including primary liver cancer, gynecologic cancer and genitourinary cancer.…”

Section: Phenotype Classification and Early Detection Of Tumor Patientsmentioning

confidence: 99%

Metabolomics for tumor marker discovery and identification based on chromatography–mass spectrometry

Yin

2013

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Early detection is the most effective way to improve the clinical outcome of malignancies. Although some tumor markers are now widely used in the clinic, their sensitivity and specificity are still not satisfactory. Thus, there is an urgent requirement for the discovery of new tumor markers. By measuring holistic endogenous metabolites, metabolomics can be used for delineating metabolic networks and discovering metabolic markers. Chromatography-mass spectrometry is the most widely used tool for metabolomics and has shown great potential for biomarker screening. In this review, the authors summarize: recent advances in the protocols and methodologies of chromatography-mass spectrometry-based metabolomics in the discovery of tumor markers; recently identified tumor metabolic markers for primary liver cancer, gynecologic cancer and genitourinary cancer and their applications; and commonly encountered problems in the translational research of metabolic markers.

show abstract

“…Cancer VOCs are produced by tumor cells, then they are exchanged and excreted via various body fluids and excreted into the endobronchial cavity [3]. Rely on these VOC profiles in urine [4], blood [5], exhaled breath [6]- [12] and tissue [13], a potentially non-invasive frontier in the diagnosis of cancer is heralded. Cytotoxicity level in cancer cells was normally express as IC 50 value (the dose necessary to cause a 50% reduction in cell viability relative to untreated control cells).…”

Section: Introductionmentioning

confidence: 99%

Rapid Identification of Cancerous Cell Lines and Evaluation of Cytotoxic Effects on Cancer Cells with VUV-PIMS

Song¹,

Wu²,

Liu³

et al. 2017

IJANER

View full text Add to dashboard Cite

show abstract

Urinary Volatile Compounds as Biomarkers for Lung Cancer

Cited by 92 publications

References 34 publications

Application and Uses of Electronic Noses for Clinical Diagnosis on Urine Samples: A Review

Application and Uses of Electronic Noses for Clinical Diagnosis on Urine Samples: A Review

Metabolomics for tumor marker discovery and identification based on chromatography–mass spectrometry

Rapid Identification of Cancerous Cell Lines and Evaluation of Cytotoxic Effects on Cancer Cells with VUV-PIMS

Contact Info

Product

Resources

About